Related Experiment Video
Updated: Jun 22, 2026

In vivo Imaging of Transgenic Leishmania Parasites in a Live Host
Published on: July 27, 2010
Exploring Mono and Bis-gold(I)-DTC Complexes Against Cancer and Leishmania
Thaiz Cristina Soares Dos Santos1, Patrícia Salvador Tessaro1, Ana Luiza de Andrade Querino1
1Laboratório de Síntese e Interações Bioinorgânicas (SibLab), Departmento de Química, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil.
Abstract:
Cancer is one of the main challenges of global public health and a leading cause of death, hindering the increase in life expectancy, and leishmaniasis occupies the second position in the number of deaths from parasitic diseases. Gold(I)-based drugs are being studied for chemotherapy and have shown promising results, leading to the search for analogs with more favorable effect profiles. This work presents the synthesis and characterization of five new gold(I) complexes, [AuIDTCPPh3] and [AuI 2DTC(PPh3)2], using dithiocarbamate-derived ligands and triphenylphosphine, with potential biological activity. The antiproliferative activity was investigated in breast tumor cell lines (MDA-MB-231 and 4T1) and a non-tumor breast cell line (MCF-10a), showing that complexation with gold enhances cytotoxic activity. The antileishmanial activity was investigated against intracellular amastigotes of Leishmania (Viannia) braziliensis, L. (Leishmania) amazonensis, and L. (L.) infantum. All complexes demonstrated promising activity, especially the bis-gold(I) complexes, which showed higher activity in the studied cell lines and Leishmania parasites. The results show the importance of the gold atom in these compounds, supporting the development of gold-based compounds as prototypes for metallodrugs.
Insights
New gold(I) complexes show potent anticancer and antileishmanial activities. These metallodrugs, particularly bis-gold(I) compounds, offer promising therapeutic potential against cancer and parasitic leishmaniasis.
Area of Science:
- Medicinal Chemistry
- Drug Discovery
- Nanotechnology
Background:
- Cancer and leishmaniasis pose significant global health challenges, driving the need for novel therapeutic agents.
- Gold(I)-based compounds are emerging as promising candidates for chemotherapy, necessitating the development of analogs with improved efficacy.
- Dithiocarbamate ligands and triphenylphosphine are utilized in the design of novel gold(I) complexes.
Purpose of the Study:
- To synthesize and characterize five new gold(I) complexes with potential biological applications.
- To evaluate the antiproliferative activity of these complexes against breast tumor cell lines.
- To assess the antileishmanial efficacy of the synthesized gold(I) complexes against various Leishmania species.
Main Methods:
- Synthesis and characterization of five novel gold(I) complexes using dithiocarbamate ligands and triphenylphosphine.
- In vitro antiproliferative assays using human breast tumor cell lines (MDA-MB-231, 4T1) and a non-tumorigenic breast cell line (MCF-10a).
- In vitro antileishmanial assays against intracellular amastigotes of Leishmania (Viannia) braziliensis, L. (Leishmania) amazonensis, and L. (L.) infantum.
Main Results:
- All synthesized gold(I) complexes exhibited enhanced cytotoxic activity against breast tumor cells compared to controls.
- The bis-gold(I) complexes demonstrated particularly potent antiproliferative effects.
- The complexes showed significant antileishmanial activity, with bis-gold(I) compounds displaying superior efficacy against Leishmania parasites.
- Gold complexation was crucial for the observed biological activities.
Conclusions:
- The novel gold(I) complexes possess significant antiproliferative and antileishmanial properties.
- Bis-gold(I) complexes represent promising lead compounds for developing new metallodrugs against cancer and leishmaniasis.
- The findings underscore the therapeutic potential of gold-based compounds in combating major global diseases.
More Related Videos
12:22A Parasite Rescue and Transformation Assay for Antileishmanial Screening Against Intracellular Leishmania donovani Amastigotes in THP1 Human Acute Monocytic Leukemia Cell Line
Published on: December 30, 2012
10:03Development of Leishmania Species Strains with Constitutive Expression of eGFP
Published on: April 21, 2023
Related Concept Videos
Immunogold Electron Microscopy
Leishmaniasis
Antiprotozoal Agents